fbpx
QQQ
+ 0.89
339.46
+ 0.26%
DIA
+ 0.07
344.91
+ 0.02%
SPY
+ 0.75
422.86
+ 0.18%
TLT
-0.23
142.77
-0.16%
GLD
-2.04
179.78
-1.15%

NewLeaf Brands Taps Mydecine Founder To Be COO, Oversee Psychedelics

May 11, 2020 2:00 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
NewLeaf Brands Taps Mydecine Founder To Be COO, Oversee Psychedelics

Cannabis development company NewLeaf Brands Inc. (CSE:NLB) (OTC: NLBIFannounced Monday it has named Damon Michaels as its new chief operations officer.

Michaels sharpened his management skills while working in Ebbu, a Colorado-based cannabis researcher, for over three years.  

He started off with administering the company's everyday operations, including the supervision of production, R&D, HR, compliance, etc.

Michaels demonstrated his guidance skills in the area of business strategy, marketing, and development, providing the company with tools to develop consistent products.

Following the Ebbu's $429 million acquisition by Canopy Growth in 2018, he served in the company management's team.

At the time, his primary focus was on the advancing medicinal mushroom market. He co-founded Mydecine Group., a Colorado-based company exploiting mushrooms and fungi for medicinal purposes.

Last month, NewLeaf Brands disclosed its attention toward acquiring Mydecine, that way, expanding to the psychedelics space.

"I've known and worked with Damon for several years in various capacities in the cannabis industry and always knew how incredibly sharp he is. Whatever Damon steps into, he goes in 110%," said NewLeaf Brands Inc.'s CEO Joshua Bartch, citing Michaels' "wild success." 

"When I caught wind that Damon was working on something in the Mycology space, I knew I had to be involved," Bartch added.

At his new position at the NewLeaf Brands, Michaels will manage the day to day operations, and oversee the mycology segment.

Michaels believes there's a considerable opportunity for utilizing fungi, aside from medicinal psychedelic research and manufacture of non-psychedelic products.

"Mydecine is poised to be a global fungi leader, especially with our amazing team dynamic and the help from collaborative efforts of others who share the same passion," Michaels said.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

'Psyched': Silo Wellness To Go Public, MindMed Adds DMT To Research Portfolio, Champignon Closes $11M Raise, Mydecine Launches New Research Partnership

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. read more

'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. read more

'Psyched': MindMed Acquires Rights For LSD Research, NewLeaf Brands To Purchase Mushroom Company

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. read more

TeaLief Maker To Acquire Medicinal Mushroom Company